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Running title: Mechanism of RGGT inhibition by bisphosphonates 
Rab geranylgeranyl transferase 
(RGGT) catalyzes the post-translational 
geranylgeranyl (GG) modification of (usually) 
two C-terminal cysteines in Rab GTPases. 
Here we studied the mechanism of the Rab 
geranylgeranylation reaction by 
bisphosphonate analogs in which one 
phosphonate group is replaced by a 
carboxylate (phosphonocarboxylate, PC). The 
phosphonocarboxylates used were 3-PEHPC, 
which was previously reported, and (+)-3-
IPEHPC, a >25-fold more potent related 
compound as measured by both IC50 and Ki. 
(+)-3-IPEHPC behaves as a mixed-type 
inhibitor with respect to GG pyrophosphate 
(GGPP) and an uncompetitive inhibitor with 
respect to Rab substrates. We propose that 
phosphonocarboxylates prevent only the 
second GG transfer onto Rabs based on the 
following evidence. First, geranylgeranylation 
of Rab proteins ending with a single cysteine 
motif such as CaaX, is not affected by the 
inhibitors, either in vitro or in vivo. Second, 
the addition of an -aaX sequence onto Rab-
CC proteins protects the substrate from 
inhibition by the inhibitors. Third, we 
demonstrate directly that in the presence of 
(+)-3-IPEHPC, Rab-CC and Rab-CXC 
proteins are modified by only a single GG 
addition.  The presence of (+)-3-IPEHPC 
resulted in a preference for the Rab N-
terminal cysteine to be modified first, 
suggesting an order of cysteine 
geranylgeranylation in RGGT catalysis. Our 
results further suggest that the inhibitor binds 
to a site distinct from the GGPP-binding site 
on RGGT. We suggest that 
phosphonocarboxylate inhibitors bind to a 
GG-cysteine binding site adjacent to the 
active site, which is necessary to align the 
monoGG-Rab for the second GG addition. 
These inhibitors may represent a novel 
therapeutic approach in Rab-mediated 
diseases. 
 
Most proteins of the Ras-like GTPase 
superfamily need to be post-translationally 
modified by prenyl groups in order to associate 
with cellular membranes and to activate 
downstream effectors (1). Protein prenylation 
involves the formation of a thioether link 
between conserved C-terminal cysteines in 
protein substrates and farnesyl pyrophosphate 
(FPP) or geranylgeranyl pyrophosphate (GGPP) 
(2,3). These prenyl pyrophosphates, which 
originate from the mevalonate pathway are 
utilized by three different prenyltransferase 
enzymes (2,3). Farnesyl transferase (FT) and 
Geranylgeranyl transferase type I (GGT-I) 
transfer FPP or GGPP, respectively, to a cysteine 
residue in the context of a C-terminal CaaX 
motif, where C is a cysteine, a is an aliphatic 
residue and X is any amino acid. X contributes 
significantly to substrate specificity in FT and 
GGT-I (2). Rab geranylgeranyl transferase 
(RGGT) is distinct from FT and GGT-I in that it 
specifically recognizes Rab proteins, which vary 
in their C-terminus containing CCXX, XCXC, 
XXCC, CCXXX, CaaX and other motifs (3). 
RGGT exhibits exquisite specificity for Rabs 
due to the strict requirement of Rab Escort 
Protein (REP), which is a general Rab-GDP 
binding protein (4). RGGT is a heterodimeric 
enzyme consisting of a 60 kDa α-subunit and a 
38 kDa β-subunit, and shares 30% homology 
with its FT and GGT-I counterparts (5). The α-
subunit associates with REP in a very small area 
compared to the entire surface occupied by the 
complex, while the β-subunit binds one molecule 
of GGPP in a large hydrophobic cavity (5,6).  
Although a large number of specific FT 
and GGT-I inhibitors have been developed as 
potential anti-cancer agents (7,8), few inhibitors 
of RGGT exist. Recently the 
phosphonocarboxylate 3-PEHPC, was identified 
as a specific RGGT inhibitor, thereby selectively 
preventing the prenylation of Rab proteins in 
cells (9,10). This compound was derived from 
the bisphosphonate (BP), risedronate, which is 
used clinically in the treatment of osteoporosis, 
due to its ability to potently inhibit the activity of 
bone-resorbing osteoclasts (11). Although BPs 
such as risedronate prevent Rab prenylation, 
they do not act by inhibiting RGGT. Rather, 
these drugs prevent the synthesis of FPP and 
GGPP by inhibiting FPP synthase, thereby 
preventing all protein prenylation (12). 3-
PEHPC is a weak RGGT inhibitor and 
consequently a weak inhibitor of bone 
resorption. However, we have recently identified 
a similar phosphonocarboxylate, (+)-3-IPEHPC, 
which is at least 25 times more potent than 3-
PEHPC as an inhibitor of RGGT. Here, we 
report the surprising finding that 
phosphonocarboxylate inhibitors of RGGT act 
by inhibiting only the second Rab 
geranylgeranylation event, therefore providing 
specificity towards Rab proteins with a double 
cysteine C-terminal motif.  
 
Experimental procedures 
 
Plasmid constructs – Human REP1 
cDNA was cloned into pFastBacHTb and 
produced as described previously (13). Rat 
RGGT was prepared as described previously 
(13). Canine Rab1a, human Rab27a, human 
Rab5a, human Rab18, human Rab6a were 
amplified by PCR and cloned into pET14b and 
human Rab13 and mouse Rab23 were cloned 
into pGEX-4T-1 as described previously (14). 
The indicated C-terminal sequence mutants were 
obtained by using the Quickchange mutagenesis 
kit (Stratagene). The sequences of all plasmid 
constructs used were confirmed by DNA 
sequencing. 
Recombinant Proteins - The 
recombinant proteins RGGT and REP1 were 
prepared by infection of Sf9 cells with 
recombinant baculoviruses encoding each 
subunit of the desired enzyme and purified by 
nickel Sepharose-affinity chromatography as 
described previously (13,15). Recombinant 
6xHis and GST-tagged Rab proteins were 
purified by nickel sepharose or glutathione 
sepharose affinity as described previously 
(16,17). All recombinant proteins were snap 
frozen in small aliquots and stored at - 80°C until 
use. 
Bisphosphonates - 2-Hydroxy-2-
phosphono-3-pyridin-3-yl-propionic acid (3-
PEHPC, previously referred to as NE-10790) [1] 
was a gift from Procter & Gamble 
Pharmaceuticals. 2-Hydroxy-3-imidazo[1,2-
a]pyridin-3-yl-2-phosphonopropionic acid (3-
IPEHPC) [2] was synthesized and resolved into 
its component enantiomers by methods reported 
elsewhere (McKenna et al., manuscript in 
preparation).The (+)-enantiomer was used in the 
present study, since this has been shown to be 
selective towards RGGT, and a more potent 
inhibitor of this enzyme than the (-)-enantiomer 
(McKenna et al., manuscript in preparation). The 
enantiopurity was determined to be > 98 % by 
chiral HPLC using a Prontosil AX QN (eluted 
isocratically with 0.7 M TEAA buffer containing 
75 % MeOH at pH 5.8; UV detection at 265 nm, 
flow rate 3 ml/min). The more active (+)-
enantiomer elutes first. The specific optical 
rotation [α]D25 +109 ° was measured on a Jasco 
J100 Polarimeter. 
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In vitro prenylation assay - RGGT 
activity was measured by determining the 
amount of [3H] GGPP transferred to Rab 
proteins (15,18). Unless otherwise indicated, the 
standard reaction mixture contained the 
following concentrations in a final volume of 
25μl: 50mM sodium HEPES (pH 7.2), 5mM 
MgCl2, 1mM Nonidet P-40, 1mM 
dithioerythritol (DTE), 5μM [3H] GGPP 
(specific activity = 800 dpm/pmole), 4μM Rab 
proteins, 2μM REP1 and 50nM RGGT. After 20 
min at 37°C, the reaction was stopped by 
addition of 1ml of Ethanol/HCl (9:1) and the 
incorporated radioactivity was measured by 
filtration on glass fiber followed by scintillation 
counting (18). 
Kinetic Analyses - For the inhibition 
pattern experiments with biphosphonate 
compounds, data were collected for times where 
product accumulation was linear. The observed 
initial velocity data were fitted to equation 1 for 
mixed-type inhibition, where Km is the Michaelis 
constant for the varied substrate S, and Ki is the 
mixed-type inhibition constant for (+)-3-
IPEHPC and 3-PEHPC. 
 
For uncompetitive inhibition the observed initial 
velocity data were fitted to equation 2. 
 
The Ki and associated SEM for (+)-3-IPEHPC 
and 3-PEHPC were calculated using shared 
parameter curve fitting for all inhibitor 
concentrations using the average of duplicate 
determinations. The error represents the 
divergence between fitted curves. 
Proteolytic digestion of prenylated Rab 
proteins and peptide analysis - The peptides 
were prepared essentially as described 
previously (19,20). The RGGT mixture (25μl), 
2μM REP1, 50nM RGGT, 5μM Rab proteins, 
5μM GGPP (specific activity = 1600 
dpm/pmole) was precipitated by addition of cold 
acetone (1ml) for 1h at 4°C. The pellet was 
washed with 1ml of cold acetone and 
resuspended in 100μl of 25mM Tris-HCl (pH 8), 
4% CHAPS, 1mM EDTA and 3μg of 
endoproteinase C-Lys (Boehringer Mannheim) 
and incubated overnight at 37°C. The resulting 
peptides were isolated on a reverse-phase μRPC 
C2/C18 SC 2.1/10 column (Pharmacia) using a 
SMART System chromatography instrument 
(Pharmacia). The column was equilibrated in 
MilliQ water with 0.06% trifluoroacetic acid 
(TFA) at room temperature at a flow rate of 
200μl/min. 50μl of sample were injected and the 
peptides were separated by a 3.5ml linear 
gradient (0-70% acetonitrile) and 2.5ml of 100% 
acetonitrile (0.056% TFA). The radioactivity in 
each fraction (200μl) was measured by 
scintillation counting (Beckman LS 6000SC). 
[3H]GGPP binding to RGGT – The 
reaction mixture (25μl), 2μM REP1, 100nM 
RGGT, 4μM Rab proteins, 2μM [3H]GGPP 
(specific activity = 4500 dpm/pmole), 100μM 
(+)-3-IPEHPC was incubated for 20min at 37°C 
and was mixed with 2μl of rabbit anti-RGGT 
(H492) plus 25μl of protein G beads (GE 
healthcare). The solution was gently shaken for 
2h at 4°C. The beads were washed 4 times with 
1ml of PBS and the proteins were precipitated by 
adding 200μl of EtOH:HCl (9:1). The samples 
were centrifuged at 20,000 x g for 10min and the 
radioactivity in 200μl of supernatant was 
determined by scintillation counting. 
Analysis of prenylation of GFP-Rabs in 
293 cells – Human Embryonic Kidney 293 (293) 
cells were grown in DMEM medium 
supplemented with 10% FCS and seeded into 
12-well plates at 2x105 cells/well. The following 
day, cells were transfected with 400ng of 
purified plasmids (the EGFP-Rab constructs 
detailed above) using Fugene6 transfection 
reagent, according to the manufacturer’s 
instructions (Roche). Immediately after 
transfection, 0-1.5 mM 3-PEHPC, was added to 
the culture medium and cells incubated for 24H. 
Cells were then lysed in Triton X-114 
fractionation buffer, and prenylated Rabs 
separated from unprenylated Rabs as previously 
described (9). 30μg of fractionated lysates 
(aqueous and detergent-rich phases, containing 
unprenylated and prenylated Rabs, respectively) 
were electrophoresed on 12% polyacrylamide 
Criterion gels (Bio-Rad), transferred to PVDF 
membrane, then western blotted for GFP-Rabs 
using an anti-GFP antibody and also β-actin as a 
loading control (Sigma). Bands were visualized 
following hybridization with secondary 
antibodies conjugated to AlexaFluor-680 and 
AlexaFluor-800 using an Odyssey infra-red 
imaging system (LiCor). 
Analysis of localization of GFP-Rabs in 
293 cells - 293 cells were seeded onto 9 mm 
glass coverslips in 48 well plates at 4x104 
cells/well, then transfected the following day 
with 100ng of EGFP-Rab constructs using 
Fugene6. In some cases, cells were also 
incubated with 1mM 3-PEHPC. Cells were 
incubated for 24H, then fixed in 4% 
formaldehyde. Nuclei were counterstained with 
TO-PRO-3 iodide and the cells were examined 
using a Zeiss LSM510 META confocal 
microscope after mounting the coverslips onto 
glass slides. 
Icmt assay - Enriched Icmt membranes 
were a kind gift of Patrick J. Casey (Department 
of Pharmacology, Duke University). The 
methylation of Rab1a was measured after in 
vitro prenylation of the protein. The final volume 
on prenylation reaction (25μl) contains: 50mM 
sodium HEPES (pH 7.2), 5mM MgCl2, 1mM 
DTE, 20μM cold GGPP, 10μM Rab1a proteins, 
2μM REP1, 100nM RGGT and 100μM (+)-3-
IPEHPC. After 30 min at 37°C, 5μl of buffer 
50mM sodium HEPES (pH 7.2), 5mM MgCl2, 
1mM DTE, 10μM [3H] S-adenosyl methionine 
(specific activity = 650 dpm/pmol) and 1 μg of 
enriched Icmt membranes were added for 40 
min. The reaction was stopped and treated as 
described previously. 
 
Results 
 
PCs are mixed-type inhibitors of RGGT. 
We previously reported weak RGGT inhibition 
by a racemic phosphonocarboxylate compound, 
3-PEHPC (10). The pyridine cycle of this 
compound was replaced by an imidazo[1,2-
α]pyridine cycle to create (+)-3-IPEHPC, a PC 
analogue of the BP, minodronate.  We found that 
(+)-3-IPEHPC was 25-fold more potent for 
RGGT inhibition compared to 3-PEHPC using 
Rab1a as the substrate (IC50 (+)-3-IPEHPC = 1.3 ± 
0.22 μM; IC50 3-PEHPC = 31.9 ± 2.1 μM; Table 1 
and Figure 1). To assess the inhibition type with 
respect to both substrates, Rab and GGPP, we 
designed kinetic experiments using (+)-3-
IPEHPC. Double-reciprocal plots obtained from 
such experiments are shown in Figure 2A for 
Rab and Figure 2B for GGPP. Equations 
describing competitive, noncompetitive, 
uncompetitive and mixed-type inhibitions were 
fitted to the data for Rab1a, resulting in a best fit 
for an uncompetitive inhibition (Figure 2A); the 
calculated Ki under the conditions employed in 
this assay was 0.21 ± 0.09 μM. Similar analysis 
for the lipid substrate, GGPP, suggests a mixed-
type inhibition, ie, the inhibitor behaves both as 
competitive and noncompetitive inhibitor 
(Figure 2B); we calculated that Ki = 0.074 ± 
0.029 μM. Interestingly, 3-PEHPC gave a 
similar type of inhibition for both substrates with 
Ki values of 5 ± 0.18 μM and 33.6 ± 11.1 μM for 
GGPP and Rab1a substrates respectively (Table 
2). 
 
Inhibition of Rab prenylation by PCs is 
dependent on the C-terminal prenylation motif. 
The velocity of the prenylation reaction can be 
described as vt = v1*v2, where vt is the total 
velocity of the reaction and v1 and v2 the 
velocities for the addition of the first and the 
second GGPP, respectively. To assess the 
possibility that different forms of the 
enzyme/substrate complex are unequally 
sensitive to (+)-3-IPEHPC, we measured IC50 
values for Rab1a substrates with different C-
terminal motifs. To generate mono-prenylated or 
di-prenylated products at different C-terminal 
positions, the –CC motif of Rab1a was replaced 
by CSC, CCS, CS, or SC, and the respective 
recombinant proteins were produced as His 
tagged fusion proteins in E. coli and purified. In 
vitro prenylation assays were then performed 
with those substrates at different inhibitor 
concentrations (Table 1). The IC50s generated for 
Rab1a-CC, Rab1a-CSC and Rab1a-CCS proteins 
were very similar, at around 1 μM. This result 
suggests that different double-cysteine motifs in 
the context of the same Rab does not affect 
significantly the inhibition by (+)-3-IPEHPC. 
Conversely, the IC50 varied with the Rab 
substrate used. Comparing different Rab proteins 
containing double cysteine motifs, Rab1a (CC), 
Rab5a (CCSN), Rab6a (CSC) and Rab27a 
(CGC), we observed a 30-fold higher IC50 for 
Rab6 as compared with Rab1a, Rab5a and 
Rab27a (Table 1). Similar differences were 
found when we measured IC50 values for 3-
PEHPC, which was 50-fold higher for Rab6 
substrate compared to Rab27a.  
We next determined whether other 
factors in the C-terminal motif affected the 
inhibitory properties of PCs. In the context of 
Rab5a (CCSN), changing to –CCQNI (present in 
Rab11a), resulted in an increase in IC50 from 0.4 
μM to 16.5 μM for (+)-3-IPEHPC (Table 1), 
whereas when the motif was changed to 
CCVLL, the IC50 was increased to a lesser extent 
(IC50 = 5.9 μM) (Table 1). Similar differences 
were found using (+)-3-PEHPC as the inhibitor 
(Table 1). Both C-terminally modified Rab5 
proteins were doubly-geranylgeranylated as 
verified by chromatography as described below 
(data not shown). The spatial alignment of the 
CCVLL and the CCQNI sequences showed high 
similarity in terms of surface area and length, but 
the CCQNI sequence was much more 
hydrophilic than CCVLL (the grand average of 
hydropathy coefficients or GRAVY are 0.5 and 
3.36, respectively). Therefore, the length and the 
polarity of the C-terminal prenylation motif is an 
important factor in influencing the inhibitory 
properties of PCs. 
Surprisingly, (+)-3-IPEHPC no longer 
behaved as an inhibitor when single-cysteine 
Rabs were used in the assay. We studied three 
wild type proteins, Rab13 (CSLG, as a GST 
fusion), Rab18 (CSVL, as a GST fusion) and 
Rab23 (CSVP), and in all three cases no 
significant inhibition was obtained with (+)-3-
IPEHPC concentrations of up to 800 μM (Table 
1). Consistently, both Rab5a (Rab5aCVLL) and 
Rab27a (Rab27aCVLL) single-cysteine mutants 
showed the same pattern (Table 1). Furthermore, 
Rab1a mutants with a single prenylatable 
cysteine (Rab1a-CS and Rab1a-SC) exhibited a 
100-fold increase in IC50 values for (+)-3-
IPEHPC when used as substrates (221 ± 11 and 
187 ± 8 μM, respectively) as compared to the 
wild-type Rab1a-CC (Table 1). These results 
indicate that the C-terminal sequence of the Rab 
substrates plays a critical role in determining 
susceptibility to inhibition by PCs, with the 
mono-geranylgeranylated (mono-GG) Rab 
proteins unaffected, or only partially affected by 
the compound, and suggest that the first event of 
prenylation (v1) is not affected by the inhibitor. 
This model could also explain why (+)-3-
IPEHPC behaved as a mixed-type inhibitor. The 
compound may act differently for each 
prenylation reaction, v1 and v2, i.e., the different 
transition states for single and double 
prenylation.  
 
PCs inhibit only the second event of 
prenylation. To test our hypothesis that only the 
second prenylation event is inhibited by (+)-3-
IPEHPC, we developed a chromatographic 
method to discriminate between mono-
geranylgeranylated and di-geranylgeranylated 
forms of Rab proteins. Initially, we defined the 
elution volumes of mono-geranylgeranylated and 
di-geranylgeranylated peptides. We subjected 
Rab1a-CC, Rab1a-CS and Rab1a-SC to in vitro 
prenylation and the products of the reaction were 
digested by Endoproteinase C-Lys. The peptides 
obtained were separated on a C2/C18 reverse 
phase column with an acetonitrile/water gradient 
and the elution of [3H] GGPP-labelled fractions 
were analyzed (Figure 3). Under the conditions 
of the experiment, a clear separation was 
achieved between mono- and di-
geranylgeranylated peptides. Rab1a-CC 
digestion profile showed a single peak eluting at 
95% acetonitrile (fraction 24) whereas the 
Rab1a-CS and SC peptides eluted as a single 
peak at 75% acetonitrile (fraction 18) (Figure 3). 
Then, we performed in vitro prenylation 
reactions with Rab1a-CC in presence or absence 
of (+)-3-IPEHPC at a saturating concentration 
(100μM). Strikingly, in the presence of (+)-3-
IPEHPC, the di-geranylgeranylated peak 
disappeared, while a peak corresponding to 
mono-geranylgeranylated peptide appeared 
(Figure 3). Moreover, an identical profile was 
obtained when Rab1a-CSC or Rab5 (CCSN) 
were used as substrates, as well as when the 
proteins were digested with trypsin instead of 
endoproteinase C-Lys (data not shown). 
Furthermore, we detected mono-GG proteins 
when RGGT was treated with 3-PEHPC, similar 
to the results obtained with (+)-3-IPEHPC (data 
not shown). These results clearly indicate that 
only the second prenylation event is inhibited by 
PC compounds, and that the C-terminal ending 
of Rab proteins is a critical determinant of 
susceptibility to inhibition. 
 
(+)-3-IPEHPC does not preclude GGPP binding 
to RGGT. Based on the competition experiments, 
the inhibitor should not compete for substrate 
binding to RGGT, or only partially in case of 
GGPP. To assess the association of GGPP with 
the enzyme, we performed in vitro prenylation 
assays with or without (+)-3-IPEHPC. Then, we 
analyzed GGPP molecules associated with 
RGGT by immunoprecipitation of the enzyme 
using protein-G beads coupled to rabbit anti-
RGGT antibody. Excess GGPP was removed by 
extensive washing of the beads. The RGGT-
bound GGPP was then separated from Rab-GG 
by methanol extraction as Rab-GG precipitates 
under these conditions. In the absence of 
inhibitor, RGGT-bound GGPP was isolated 
when no Rab substrate was added, consistent 
with the existence of a stable GGPP binding site 
(Figure 4). As the yield of enzyme after 
immunoprecipitation is approximately 50%, 
approximately 80% of RGGT was loaded 
with radiolabeled GGPP under these 
conditions (Figure 4). This RGGT-bound 
GGPP disappeared in the presence of Rab1a-CC, 
but not in the presence of Rab1a-CS (Figure 4). 
These results suggested that the inability to 
doubly-geranylgeranylate Rab1a-CS led GGPP 
to remain stuck in the GGPP binding site. The 
inhibitor did not compete for the RGGT-bound 
GGPP in the absence of Rab protein, or in the 
presence of Rab1a-CS, indicating that it does not 
preclude the binding of GGPP to RGGT (Figure 
4). These results strongly suggest that the 
inhibitor binds to a site that is distinct from the 
GGPP-binding site on RGGT. Interestingly, 
when inhibitor and Rab1a-CC were both 
incubated with the enzyme, RGGT-bound GGPP 
could now be elicited (Figure 4). This result 
suggests that the presence of inhibitor with 
Rab1a-CC leads to freezing of GGPP on the 
RGGT-binding site, as when Rab1a-CS is 
present (in the absence of inhibitor). In both 
cases, the presence of GGPP stuck on RGGT 
may reflect an inhibition of GG transfer due to 
an inability of the monoprenylated Rab protein 
to move to a second site on RGGT, which 
accepts a newly transferred GG-cysteine.  
 
Prenylation and localization of doubly-
prenylated Rab proteins is disrupted by PCs in 
293 cells. To assess whether the susceptibility of 
Rabs with different C-terminal motifs to 
inhibition by PCs in intact cells matched the in 
vitro assays, we transfected 293 cells with GFP-
Rab constructs (Rab1A, Rab5, Rab6, and Rab18) 
and analyzed the ability of 3-PEHPC to inhibit 
prenylation in vivo and disrupt the localization of 
these Rab proteins (Figure 5). Accordingly, we 
found that prenylation of GFP-Rab1a, GFP-
Rab5a and GFP-Rab6a was susceptible to 
inhibition by 3-PEHPC, as evidenced by their 
significant shift from the detergent phase 
(prenylated forms) to the aqueous phase 
(unprenylated form) upon Triton X-114 
partitioning of cell lysates (Figure 5A).  In this 
experiment, the over-expression leads to the 
presence of a proportion of EGF-Rab in the 
aqueous phase even at steady-state. Moreover, 1 
mM 3-PEHPC completely prevented the specific 
membrane targeting of Rab1a, Rab6a and Rab5a, 
resulting in a diffuse cytoplasmic localization of 
these Rabs (Figure 5B), without affecting the 
growth or viability of the cells over this culture 
period (data not shown). Reflecting the enzyme 
inhibition data, the order of potency for 
inhibition of prenylation by 3-PEHPC was 
Rab5a>Rab1a>Rab6. In contrast, both the 
prenylation and subcellular localization of the 
mono-prenylated, CaaX motif-containing Rab18, 
was resistant to 3-PEHPC treatment, in 
agreement with the enzyme assays. Furthermore, 
despite containing a CaaX motif, the prenylation 
and subcellular localization of Rab18 was also 
unaffected by GGTI-298, a specific inhibitor of 
GGT-I (data not shown).   
 
Order of prenyl addition on Rab 
proteins. Two previous studies examined the 
order of GG addition by RGGT and proposed 
that the N-terminal cysteine is preferred to the C-
terminal one (16,21). However the substrates 
used in those studies were single-cysteine 
mutants of Rab1a and a fluorescent derivative of 
GGPP, respectively, and not native substrates. 
Since PCs specifically block only the second 
event of prenylation, they are useful tools to 
characterize the first event of Rab prenylation. 
We took advantage of the fact that the Isoprenyl 
cysteine methyltransferase (Icmt) can only 
methylate the C-terminal geranylgeranylated 
cysteine in a CaaX or CXC motif and not in the 
context of a CC motif (14). Using a coupled 
prenylation/methylation assay in vitro, we 
observed as expected, methylation of the Rab1a-
SC mutant but not of the Rab1a-CS mutant or 
wild type Rab1a-CC (Figure 6), which is 
consistent with double prenylation of the CC 
motif, as previously reported (14). Furthermore, 
the Rab1a-SC mutant was methylated by Icmt in 
the presence or absence of inhibitor, confirming 
the recognition of this motif by the 
methyltransferase and validating the 
experimental approach. Note that the inhibitor 
concentration used in the experiment (100 μM) 
was below the IC50 for Rab1a-CS or SC mutants 
and therefore would have had little effect on the 
prenylation reaction. Treatment with (+)-3-
IPEHPC did not lead to increased methylation of 
Rab1a-CC, indicating that prenylation of the N-
terminal cysteine is not affected by the inhibitor. 
Furthermore, when the Rab1a-CSC mutant was 
treated with 3-IPEHPC, we observed a dramatic 
reduction in methylation compared to untreated 
reaction, indicating that prenylation of the C-
terminal cysteine is inhibited by 3-IPEHPC, i.e., 
this is the second prenylation step. Similar 
experiments with wild type Rab27a (CGC) 
showed identical results (data not shown). These 
results demonstrate that the N-terminal cysteine 
in dual-prenylated Rabs is preferred for the first 
GG addition. 
 
Discussion 
 
We report here a mechanism of action 
for inhibition of RGGT by PCs. Our data 
suggests that these inhibitors act as partial 
inhibitors of the geranylgeranylation reaction, 
effectively inhibiting only the second GG 
addition onto those Rab substrates that contain 
double cysteine motifs at their C-terminus. Yet, 
these behave as effective inhibitors in cell 
studies presumably for two reasons. One is that 
the majority of Rabs are doubly-
geranylgeranylated and the second is that the 
enzyme exhibits highest affinity for mono-
prenylated intermediates in the reaction (16), 
raising the possibility that these inhibitors 
sequester the cellular pools of the enzyme in 
non-productive complexes.  Additionally, mono-
geranylgeranylation of normally di-
geranylgeranylated Rabs, such as Rab5, leads to 
mistargeting to the endoplasmic reticulum, and 
loss-of-function (17). Therefore, even if a 
proportion of inhibitor-induced mono-GG Rabs 
were able to interact with membranes, they 
would not be present at the correct cellular 
location.  
A limiting factor to mechanistic studies 
until now has been the relatively low affinity of 
3-PEHPC, the previously reported PC inhibitor 
of RGGT (10). In this work, we took advantage 
of a newly synthesized PC derivative, (+)-3-
IPEHPC, which we found to be substantially 
more potent (≥25-fold) than 3-PEHPC at 
inhibiting RGGT for all the Rab substrates that 
we tested. The kinetic characterization of RGGT 
inhibition by these PCs revealed that both 
compounds are uncompetitive inhibitors with 
respect to the Rab protein substrate and mixed-
type inhibitors with respect to GGPP. We then 
investigated in more detail the mechanism of 
inhibition. Using Rab1a C-terminal mutants 
(CSC, CCS, CS and SC), we observed that in the 
presence of the singly prenylated substrates, the 
efficacy of inhibition was severely impaired. 
Moreover, the prenylation of Rab proteins with a 
CaaX motif (Rab13, Rab18 and Rab23) was not 
inhibited by (+)-3-IPEHPC. We hypothesized 
that only the second event of prenylation is 
targeted by the PCs and we verified the state of 
Rab1a and Rab27a prenylation after treatment 
with PCs. In both cases, the prenylated 
substrates were modified on a single cysteine, 
demonstrating that the inhibitors block the 
second addition of GGPP.  
What could be the molecular basis for 
the inhibition of the second GG transfer? One 
possibility is that the inhibitors could be 
interfering with the complex rearrangements that 
must occur on the active site of RGGT before 
the prenylation of the second cysteine in order to 
remove the first prenyl-cysteine and allow the 
alignment of that second cysteine with the newly 
bound second GGPP substrate. Interestingly, 
Beese and colleagues described several reaction 
intermediates in the FT and GGT-I reactions that 
allowed us to create a model for the inhibitory 
mechanism. These authors showed that soaking 
FT:prenylated peptide or GGT:prenylated 
peptide crystals with FPP or GGPP respectively, 
led to the movement of the prenylated cysteine 
from the active site to a new binding site in a 
solvent accessible groove, instead of dissociation 
from the enzymes (22,23). The authors further 
proposed that a similar process could occur in 
the RGGT reaction where the first GG-cysteine 
could be translocated to a nearby second site, 
allowing the second GG transfer to proceed (22). 
Our present studies raise the hypothesis that the 
PC inhibitors bind to this second site for the 
following reasons. First, experiments measuring 
the binding of GGPP to RGGT showed that the 
inhibitors do not preclude GGPP binding and 
thus suggest that the inhibitors do not bind to the 
GGPP-binding site. Second, the same 
experiments showed that the presence of 
inhibitor froze GGPP in its binding site 
suggesting that it is inhibiting GGPP transfer by 
preventing its movement away from the GGPP-
binding site. Third, the uncompetitive kinetics 
vis-à-vis Rab substrates suggest that the 
inhibitors do not bind to the peptide-binding site.  
 The mechanism of RGGT inhibition by 
3-PEHPC has been studied using a fluorescent 
analogue of GGPP (NBD-FPP) and Rab7a 
(ending in CXC) in a continuous fluorimetric 
assay (21). Strikingly, the authors observed that 
the use of NBD-FPP led to the formation of 
predominantly mono-prenylated Rab7, and not 
doubly-prenylated as observed using the native 
substrate (24). This inability of NBD-FPP to be 
used in the second GG addition suggests an 
obvious reason for the discrepancies between the 
studies. Furthermore, the present studies suggest 
that this behaviour of NBD-FPP may be related 
to an inability to bind the putative second site on 
RGGT. Recently, another study reported on the 
identification of novel RGGT inhibitors (25). 
These inhibitors appear to act via a different 
mechanism, probably binding to the peptide site 
as they exhibit competitive kinetics with respect 
to Rab and uncompetitive kinetics with respect 
to GGPP. Nevertheless, all effective inhibitors of 
this class required a hydrophobic tail, suggesting 
the possibility that binding to the putative second 
site may also be a feature of the inhibitory 
mechanism of these compounds.  
Our results imply that the prenylation 
mechanism for singly- and doubly-prenylated 
Rab proteins may be different. Indeed, the 
prenylation of Rab5a-CVLL is not inhibited by 
PCs, whereas the prenylation of Rab5a-CCVLL 
is. The present data suggests that non-productive 
ESI complexes do not form in the presence of 
Rab-CaaX substrates, and RGGT is able to 
dissociate from the monoGG-Rab after 
prenylation. In these cases, the aaX peptide 
appears to be of importance because Rab1a-SC 
or Rab1a-CS are sensitive to inhibition, albeit at 
high concentrations of the inhibitors (200-fold 
increase compared to Rab1a WT proteins) whilst 
Rab-CaaX substrates are resistant. One 
possibility is that the aaX tail may prevent the 
use of the putative second site, which would 
allow the ready-release of the product from the 
enzyme. Further work will be necessary to 
understand the molecular basis for these 
differences.  
Finally, we utilized the ability of PCs to 
inhibit the second event of prenylation to 
demonstrate that the N-terminal cysteine of 
doubly prenylated Rabs is preferred for the first 
event. This is in agreement with our previous 
report using Rab1a-CS and Rab1a-SC substrates 
showing that the N-terminal cysteine is more 
efficiently prenylated than the C-terminal 
cysteine (16). Moreover, it was reported the first 
event of Rab7 prenylation was slower than the 
second one (26) and the prenylation of a Rab7-
SXC mutant was 3-fold faster than a Rab7-CXS 
mutant one (21), suggesting the N-terminal 
cysteine being somewhat preferred for the first 
prenylation event. We took advantage of the fact 
that Icmt can only methylate prenylated-cysteine 
when present at the extreme C-terminus (14,27). 
Here, we observed that Rab1a-CC and Rab1a-
CSC substrates in the presence of inhibitor are 
not methylated by Icmt (Figure 6), which 
strongly suggests that the N-terminal cysteine of 
double-cysteine containing-Rabs is preferentially 
prenylated.  
In summary, we have characterized the 
mechanism of RGGT inhibition by the PC 
compounds, (+)-3-IPEHPC and 3-PEHPC. These 
inhibitors do not prevent the substrates binding 
to RGGT, but block the second event of 
prenylation possibly by binding to a second 
prenyl-binding site, to which the first prenyl-
cysteine moves into to allow the second GG 
addition.  Crystallisation of 3-IPEHPC:RGGT 
and/or 3-IPEHPC:REP:RGGT:Rab complexes 
should reveal this putative binding site and the 
reaction transition states during the complex 
double geranylgeranylation reaction of Rab 
proteins. These inhibitors might represent useful 
novel therapeutic agents in Rab-mediated 
diseases. 
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Figure legends 
 
Figure 1. Inhibition of RGGT activity  by phosphonocarboxylates. Final concentrations for the 
reaction mix are REP1 (2μM), RGGT (50nM), GGPP (5μM), Rab1a (4μM) and increasing concentrations 
of (+)-3-IPEHPC (○) and 3-PEHPC (●). The reactions were incubated for 20 min at 37ºC. The values 
represent the means determined from duplicate determinations of two independent experiments. This 
experiment is representative of two other independent experiments. 
 
Figure 2. Characterization of the inhibition of RGGT by (+)-3-IPEHPC. (A) Lineweaver-Burk plot 
for the inhibition of RGGT by (+)-3-IPEHPC when Rab1a was the varied substrate. Prenylation assays 
(see Experimental Procedures) were carried out in the presence of a fixed concentration of GGPP substrate 
(5 μM) and the indicated concentrations of Rab1a at 0 (●), 0.75 (○), or 2 μM (▼) (+)-3-IPEHPC. Data 
were fit to eq 1. (B) Lineweaver-Burk plot for the inhibition of Rab1a prenylation when GGPP was the 
varied substrate. RGGT assays (see above) were carried out in the presence of a fixed concentration of 
Rab1a substrate (4 μM) and the indicated concentrations of GGPP at 0 (●), 0.5 (○), or 1 (▼) (+)-3-
IPEHPC. Data were fitted to eq 1. For both panels, data represent the means of duplicate determinations 
from a single experiment that is representative of three such experiments. 
 
Figure 3. C18 reverse-phase HPLC analysis of [3H]GG-labeled Rab1a tryptic peptides. Rabla-CC 
(●), Rab1a-CS (○), Rab1a-SC (▼) and Rab1a-CC + (+)-3-IPEHPC (100μM) ( ) were incubated 
separately with [3H] GGPP and RGGT/REP1, and digested with endoproteinase C-Lys. The respective 
digestion mixtures were then purified by reverse-phase HPLC (μRPC C2/C18 SC 2.1/10 column) using a 
SMART System, and the radioactivity of each fraction was plotted versus the eluted fractions. We 
observed similar results when the reaction mix was digested with trypsin. This experiment is 
representative of three independent experiments. 
 
Figure 4. GGPP binding to RGGT. The prenylation mix (20μl) contains REP1 (2μM), RGGT (100nM), 
Rab1a (4μM) substrate, GGPP (2μM) and as indicated on the graph 100μM (+)-3-IPEHPC. After 30 min. 
at 37°C, 2μl of polyclonal anti-RGGT (H492) and 25μl of protein G beads were added to reaction mix and 
gently agitated for 2H at 4°C. The beads were washed with PBS and the immo-complexes were 
precipitated. GGPP molecules associated with RGGT were recovered in the supernatant and detected by 
scintillation counting. Background of the reaction (solution without RGGT) was removed from each 
observed condition. Data represent the mean of four different experiments. 
 
Figure 5. Prenylation and localization of GFP-Rab constructs was analyzed following transfection of  
293 cells. (A) Transfected 293 cells were treated with 0-1 mM 3-PEHPC for 18 hours, then prenylated 
(detergent phase; D) and unprenylated proteins (aqueous phase; A) separated by triton X-114 fractionation 
and GFP-Rabs detected by western blotting using an antibody to GFP. (B) Transfected 293 cells were 
treated with  (+) or without (-) 1 mM 3-PEHPC for 18 hours, then subcellular localization of GFP-Rabs 
assessed by confocal microscopy.  
 
Figure 6. Order of prenyl addition on Rab1a. The methylation of Rab1a was measured after in vitro 
prenylation of the protein treated with (100μM) or without (+)-3-IPEHPC (for 30 min at 37ºC). 10μM of 
[3H] S-adenosyl methionine (specific activity = 650 dpm/pmol) and 1μg of enriched Icmt membranes 
were added to the reaction mix for 45 min. Proteins were precipitated and the incorporated radioactivity 
was measured. This experiment is representative of two other independent experiments. 
Table 1: IC50 values for RGGT inhibition by (+)-3-IPEHPC and 3-PEHPCa
 
Rab substrate IC50 (µM) –  (+)-3-IPEHPC 
IC50 (µM) –  
3-PEHPC 
Rab1a-CC (WT) 1.27 ± 0.24 31.85 ± 2.13 
Rab1a-CSC 1.11 ± 0.30 ND 
Rab1a-CS 221.25 ± 11.49 > 2000 
Rab1a-SC 187.82 ± 8.30 > 2000 
Rab1a-CCS 0.91 ± 0.25 ND 
Rab27a-CGC (WT) 0.83 ± 0.50 32.68 ± 1.95 
Rab27a-CVLS > 800 > 2000 
Rab5a-CCSN (WT) 0.43 ± 0.06 43.47 ± 9.85 
Rab5a-CCQNI 16.52 ± 4.42 > 2000 
Rab5a-CCVLL 5.91 ± 0.50 860 ± 80 
Rab5a-CVLL > 800 > 2000 
Rab6a-CSC 27.22 ± 2.28 1592 ± 95 
Rab13-CSLG (WT) > 800 > 2000 
Rab18-CSVL (WT) > 800 > 2000 
Rab23-CSVP (WT) > 800 > 2000 
 
a The values represent the means ± the standard error of the mean determined from duplicate 
determinations of at least two independent experiments. 
 
 
 
 
Table 2: Experimental kinetic constants for RGGT inhibition by (+)-3-IPEHPC and 3-
PEHPCa 
 
 Substrate 
Inhibitor Rab1a GGPP 
(+)-3-IPEHPC Uncompetitive 
Ki = 0.211 ± 0.091 μM 
Mixed-type 
Ki = 0.074 ± 0.029 μM 
3-PEHPC Uncompetitive Ki =  33.56 ± 11.05 μM 
Mixed-type 
Ki = 5 ± 0.18 μM 
 
a The values represent the means ± the standard error of the mean determined from duplicate 
determinations of three independent experiments. 
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